Nanotargeted agents : an emerging therapeutic strategy for breast cancer
Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 14(2019), 13 vom: 05. Juli, Seite 1771-1786 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Manling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Active targeting |
|---|
| Anmerkungen: |
Date Completed 22.06.2020 Date Revised 22.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2018-0481 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299111652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299111652 | ||
| 003 | DE-627 | ||
| 005 | 20231225095631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2018-0481 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM299111652 | ||
| 035 | |a (NLM)31298065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Manling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanotargeted agents |b an emerging therapeutic strategy for breast cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2020 | ||
| 500 | |a Date Revised 22.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a active targeting | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a nano-targeted agents | |
| 650 | 4 | |a passive targeting | |
| 650 | 4 | |a physical and chemical targeting | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Ouyang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Fansu |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Mujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Tiange |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 14(2019), 13 vom: 05. Juli, Seite 1771-1786 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:13 |g day:05 |g month:07 |g pages:1771-1786 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2018-0481 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 13 |b 05 |c 07 |h 1771-1786 | ||